Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2023 | Racial and ethnic minorities more likely to be excluded from trials based on biomarker prescreening

Underrepresentation of racially and ethnically minoritized groups in Alzheimer’s disease (AD) trials remains a significant problem, limiting the generalizability of data and fueling disparities in care. It has been suggested that differential screen failure rates due to cognitive and biomarker requirements may contribute to this underrepresentation. Doris Molina-Henry, PhD, University of Southern California, San Diego, CA, shares the findings of her work looking at plasma amyloid biomarker eligibility for the AHEAD 3-45 study (NCT04468659) among Hispanic Black (HB), Hispanic White (HW), Non-Hispanic Asian (NHA), Non-Hispanic Black (NHB), and Non-Hispanic White (NHW) groups. AHEAD 3-45 is examining the efficacy of lecanemab in individuals with preclinical AD, using plasma biomarker pre-screening in the enrolment process. Among 4274 participants, eligibility rates were lower for all minoritized groups compared to NHWs. These differences persisted regardless of APOE ε4 status. Dr Molina-Henry describes efforts to ensure that those individuals disproportionately excluded can be observed in another setting. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Doris Molina-Henry has received funding from NIA, Eisai, GHR Foundation, Alzheimer’s Assocaition and philanthropic donors.